Dynavax Technologies Corporation Культура компании

Mr. Michael S. Ostrach, J.D. has been the Chief Business Officer and Vice President at Dynavax Technologies Corporation since October 31, 2006 and serves as its Secretary. Mr. Ostrach served as the Principal Financial and Accounting Officer at Dynavax Technologies Corporation since October 15, 2013 and its General Counsel since October 31, 2006. He served as a Consultant of Amyris, Inc. (formerly Amyris Biotechnologies, Inc.). He has more than 25 years of experience as a biotechnology executive, including corporate and business development, finance, investor relations and legal affairs. Previously, he served as Chief Operating Officer and General Counsel of Threshold Pharmaceuticals Inc. from September 15, 2005 to October 2006 and served as its Chief Financial Officer until October 2006. Mr. Ostrach served as Consultant of Kosan Biosciences Inc. since August 2004, President from January 2002 to August 2004 and Chief Operating Officer from October 1998 to January 2002. He joined Kosan Biosciences Inc. in October 1997, as Vice President of Corporate Development. He spent at Kosan Biosciences from 1997 to 2004. Prior thereto, he served as an independent consultant for biotechnology companies from October 1996 to October 1997 and From 1993 to 1994. Mr. Ostrach served as Executive Vice President and Chief Operating Officer of Neurobiological Technologies, Inc., from 1994 to 1996. He served as a Senior Vice President at Cetus Corporation, from 1981 to 1991. He served as Vice President of Chiron Corporation since 1992. He founded Chiron Technologies, a Chiron business unit and served as its President. He began his corporate career at Cetus Corporation, initially as General counsel and later served as its Senior vice president of corporate affairs, General counsel and Secretary. He serves as Chairman of Supervisory Board at Rhein Biotech GmbH. He served as a Director of Amyris Biotechnologies Inc. Mr. Ostrach received his J.D. from Stanford Law School and his B.A. from the Brown University.

Dr. Robert L. Coffman, Ph.D. has been Chief Scientific Officer at Dynavax Technologies Corporation since December 2000. Dr. Coffman has been Senior Vice President of Dynavax Technologies Corporation since February 2014 and served as its Vice President since December 2000. Dr. Coffman has been Member of Scientific Advisory Board at Genocea Biosciences, Inc., since November 23, 2009. He joined Dynavax Technologies Corporation from the DNAX Research Institute where he had been since 1981, as Distinguished Research Fellow. He has made fundamental discoveries about the regulation of immune responses in allergic and infectious diseases. Dr. Coffman shared the William S. Coley Award for Research in Immunology for discovery of the Th1 and Th2 subsets of T lymphocytes, the cells that control most immune responses. He was a postdoctoral fellow at Stanford University Medical School. In 2006, Dr. Coffman was elected to the National Academy of Sciences as a Member. Dr. Coffman received his Ph.D. from the University of California San Diego and his A.B. from Indiana University.

Dr. Dennis A. Carson, Ph.D., M.D. co-founded Samumed, LLC in 2007 and serves as its Advisor. Dr. Carson serves as an Advisor at Zacharon Pharmaceuticals, Inc., Dr. Carson Co-founded Telormedix SA in 2008 and served as its Advisor. He serves as an Associate Dean for Health Sciences and Director of Moores Cancer Center at the University of California San Diego Medical Center,La Jolla, California. He serves as Member of Scientific Advisory Board at Biological Dynamics Inc. He served as Clinical Advisor of Syndax Pharmaceuticals, Inc. He founded Vical Inc., Dynavax Technologies Corp., IDEC Pharmaceuticals and Triangle Pharmaceuticals Inc. He served as a Member in the Department of Immunology at The Research Institute of the Scripps Clinic. He has been a Director at Dynavax Technologies Corporation since December 1997. He has been Director of The Rebecca and John Moores UCSD Cancer Center since 2003. Dr. Carson serves as a Member of Scientific Advisory-Board at Telormedix SA and Multimeric Biotherapeutics, Inc. He co-founded Salmedix Inc., and served as its Director since November 2000. He served as a Member of Scientific Advisory Board of Epiphany Biosciences, Inc. He has been Director of the Sam and Rose Stein Institute for Research on Aging since 1990. He is a Member of the American Academy of Arts and Sciences and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He is a Researcher in the fields of autoimmune and immunodeficiency diseases and is Co-discoverer with Dr. Eyal Raz of the immunostimulatory sequences. He holds an adjunct appointment with The Scripps Research Institute. Dr. Carson has been a Professor in the Department of Medicine at the University of California, San Diego since 1995. He joined the UCSD School of Medicine faculty in 1990 as Professor of Medicine. He is a noted Researcher in the field of lymphoproliferative diseases. He developed the drug cladribine. He is also a vaccinologist who originated the concept of DNA vaccination using intramuscular injections of DNA encoding vaccine proteins. He was inducted into the National Academy of Sciences in 2003. He has published nearly 450 scientific papers and is an inventor on more than 60 U.S. and international patents. He is an internationally respected Immunologist and Cancer Biologist. He is perhaps best known for his landmark work in developing 2-chlorodeoxyadenosine, or 2-CdA, as Division Head of Immunology Research Foundation. He is awarded by BIOCOM Life Sciences Heritage Award, the Chester Stock Award of Memorial Sloan-Kettering Cancer Center. He received the Arthritis Foundation's highest scientific honor, the Lee C. Howley Sr. Prize for Arthritis Research, an award from the American Association for Cancer Research. He was the 2004 recipient of the AACR-Bruce F. Cain Memorial Award. He received his Medical degree from Columbia University and his B.A. from Haverford College. He did his Internal Medicine training at UCSD. Dr. Carson did his Postgraduate research training at the Salk Institute and the National Institutes of Health and subsequently had an Arthritis Foundation-funded Postdoctoral Fellowship at UCSD.

Mr. David F. Novack has been Senior Vice President of Operations and Quality at Dynavax Technologies Corporation since March 25, 2013. Mr. Novack joined Dynavax Technologies from Novartis Vaccines & Diagnostics where he served as the Global Head of Technical Operations and Supply Chain for Diagnostics and as the Global Head of Vaccine Manufacturing Strategy. During his tenure at Novartis, Mr. Novack successfully developed and executed manufacturing capacity plans to meet commercial requirements, designed and executed remediation programs to be compliant with current quality standards and was responsible for cost-effective supply chain solutions across multiple product lines. Mr. Novack served as Vice President of Business Development at Vaxin Inc., a vaccine company, from 2004 to 2006. He has held a diverse range of management positions over a 15 year period in the vaccine and biopharmaceutical industry. Mr. Novack has nearly 25 years of industry experience in manufacturing and supply chain operations, implementing multi-national commercial manufacturing and supply chain strategies for both global industry leaders and emerging companies in vaccines, diagnostics and biopharmaceuticals. Mr. Novack enjoyed a 10-year career with MedImmune (formerly, Aviron), where as Senior Director, Supply Chain Operations, he developed the supply chain strategy and infrastructure for FluMist, ultimately leading to the approval and launch of the first intranasal influenza vaccine in the US. With Aviron, Mr. Novack had business development responsibilities, completing licensing deals and partnerships for several vaccine and pipeline technologies. While at Lederle (Wyeth), Mr. Novack was promoted through positions in vaccine operations, sales and marketing as part of an accelerated management development program over a 5 year period. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles. Mr. Novack received his MBA in 1989 from Columbia University and his B.S. in Biology from the State University of New York at Albany.

Dr. Robert Janssen, M.D. has been the Chief Medical Officer and Vice President of Clinical Development at Dynavax Technologies Corporation July 9, 2013. Prior to Dynavax, Dr. Janssen served as Vice President of Medical Affairs at Gilead from 2008 to 2010, where he was responsible for oversight of physician and health care provider education focused on HIV and hepatitis Btherapies. Until 2008, Dr. Janssen spent 23 years at the US Centers for Disease Control and Prevention (CDC), as the Director of the Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of pre-exposure prophylaxis for HIV.

Mr. Steven N. Gersten has been Chief Ethics & Compliance Officer, Vice President and General Counsel at Dynavax Technologies Corporation since 2015 and serves as its Secretary. Prior to joining Dynavax, Mr. Gersten served as global Vice President and Ethics and Compliance Officer at AbbVie, where he helped build the compliance program and organization. From 2002 to 2013, he was employed by Abbott Laboratories, where he served as Vice President and Chief Regulatory and Compliance Counsel and Vice President and Chief Counsel / General Counsel to several business units, setting global legal strategies and functional plans as well as overseeing the internal legal organization and external counsel. Prior to joining Abbott, Mr. Gersten held various positions of increasing responsibility with the U.S. Department of Justice (where he brought enforcement cases on behalf of the FDA), the law firms Howrey and Simon and Shea and Gould and with the U.S. Attorney's Office in Washington, D.C. Mr. Gersten holds a JD degree from the Boston University School of Law and a BS degree from Boston University School of Management.

Mr. David L. Johnson, CPA has been the Chief Accounting Officer and Vice President of Dynavax Technologies Corporation since February 5, 2014. Mr. Johnson serves as Managing Director of Macauley Johnson, LLC. He served as the Chief Financial Officer at OXiGENE, Inc. from April 2, 2012 to July 30, 2012 and as its Principal Accounting Officer until July 30, 2012. He joined OXiGENE in March 2012. He served as Chief Financial Officer of BiPar Sciences, Inc. until May 17, 2007. Mr. Johnson has been a Consultant providing financial management services to various clients on an interim or project basis since December 2002. He served at First Commonwealth Financial Corp. From January 1995 to September 1996, Mr. Johnson was an independent financial consultant and provided accounting services to Chiron, a biotechnology company. He served as the Chief Financial Officer of Kosan Biosciences Inc. from February 2006 to August 15, 2006 and also served its Principal Accounting Officer until August 15, 2006. He also served as Chief Financial Officer of Pain Therapeutics Inc. from January 2000 to November 2002. From November 1998 to December 1999, he served as an independent financial consultant, and acted as Chief Financial Officer of Aradigm. From October 1997 to November 1998. Mr. Johnson held positions as Vice President of Finance and Administration of Elan Pharmaceuticals North America and Vice President of Finance and Chief Financial Officer of Athena Neurosciences, both of which were divisions of Elan Pharmaceuticals, a pharmaceutical company. From September 1996 to October 1997, he served as Director of Finance of Gilead Sciences. From June 1993 to December 1994, Mr. Johnson served as Director of Financial Planning and Operational Analysis of Chiron. He held various financial positions at The Cooper Companies. Mr. Johnson served as Member of the Audit staff of KPMG LLP. He has been Director of OXiGENE, Inc since December 2002. Mr. Johnson received his B.S. in Accounting from Oklahoma State University.